Analysts Anticipate Alpine Immune Sciences Inc (NASDAQ:ALPN) Will Announce Quarterly Sales of $280,000.00

Brokerages expect that Alpine Immune Sciences Inc (NASDAQ:ALPN) will report $280,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Alpine Immune Sciences’ earnings, with the highest sales estimate coming in at $300,000.00 and the lowest estimate coming in at $250,000.00. The firm is expected to report its next quarterly earnings report on Monday, March 16th.

According to Zacks, analysts expect that Alpine Immune Sciences will report full-year sales of $1.03 million for the current year, with estimates ranging from $860,000.00 to $1.16 million. For the next financial year, analysts forecast that the company will report sales of $1.10 million, with estimates ranging from $1.00 million to $1.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its earnings results on Wednesday, November 13th. The biotechnology company reported ($0.62) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.06. The company had revenue of $0.29 million for the quarter, compared to analysts’ expectations of $0.38 million.

ALPN has been the subject of several research analyst reports. Zacks Investment Research upgraded Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a report on Thursday, November 28th. Piper Jaffray Companies decreased their price objective on Alpine Immune Sciences to $8.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. They noted that the move was a valuation call. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Alpine Immune Sciences presently has an average rating of “Buy” and an average target price of $9.31.

A number of hedge funds have recently added to or reduced their stakes in ALPN. Jacobs Levy Equity Management Inc. purchased a new position in shares of Alpine Immune Sciences in the 2nd quarter worth $90,000. Hikari Power Ltd grew its position in Alpine Immune Sciences by 52.9% in the third quarter. Hikari Power Ltd now owns 185,587 shares of the biotechnology company’s stock worth $735,000 after acquiring an additional 64,224 shares in the last quarter. Vanguard Group Inc. grew its position in Alpine Immune Sciences by 67.7% in the second quarter. Vanguard Group Inc. now owns 202,582 shares of the biotechnology company’s stock worth $853,000 after acquiring an additional 81,800 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Alpine Immune Sciences by 10.8% during the second quarter. Renaissance Technologies LLC now owns 106,261 shares of the biotechnology company’s stock worth $447,000 after acquiring an additional 10,400 shares during the last quarter. Institutional investors and hedge funds own 46.80% of the company’s stock.

Shares of NASDAQ:ALPN traded up $0.01 during mid-day trading on Friday, reaching $3.01. The stock had a trading volume of 1,474 shares, compared to its average volume of 28,149. The business’s 50 day moving average price is $2.89 and its 200 day moving average price is $3.98. Alpine Immune Sciences has a 1 year low of $2.25 and a 1 year high of $8.24. The company has a market cap of $55.58 million, a P/E ratio of -1.15 and a beta of 1.79. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.47.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.

Recommended Story: Trading Options- What is a Strangle?

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with's FREE daily email newsletter.